Cargando…

Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020

PURPOSE: The antimicrobial resistance profiles of gram-negative bacilli causing bloodstream infections have changed over time, while comprehensive and real-time surveillance data are limited in China. This study aimed to review the antimicrobial susceptibility trends among main gram-negative bacilli...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Mengyao, Zheng, Bo, Li, Yun, Lv, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064452/
https://www.ncbi.nlm.nih.gov/pubmed/35517902
http://dx.doi.org/10.2147/IDR.S358788
_version_ 1784699380114128896
author Yan, Mengyao
Zheng, Bo
Li, Yun
Lv, Yuan
author_facet Yan, Mengyao
Zheng, Bo
Li, Yun
Lv, Yuan
author_sort Yan, Mengyao
collection PubMed
description PURPOSE: The antimicrobial resistance profiles of gram-negative bacilli causing bloodstream infections have changed over time, while comprehensive and real-time surveillance data are limited in China. This study aimed to review the antimicrobial susceptibility trends among main gram-negative bacilli isolated from blood specimens in China. METHODS: From 2011 to 2020, a total of 4352 non-duplicate isolates were collected from 21 tertiary hospitals in 18 provinces or cities across China. Antimicrobial susceptibility testing was conducted by the agar dilution method recommended by the Clinical and Laboratory Standards Institute (CLSI), and the results were interpreted using CLSI criteria. RESULTS: During this 10-year surveillance period, meropenem and imipenem were the most effective agents against Escherichia coli (resistance remaining <5%). The proportion of ESBL-producing isolates in carbapenem-susceptible E. coli displayed a decreasing trend (from 72.9% to 51.2%). The resistance rates of Klebsiella pneumoniae to meropenem and imipenem increased from 3.3% and 1.6% in the 2011–12 period to 15.0% and 15.4% in the 2019–20 period, respectively. Carbapenems and amikacin were the most active agents against Enterobacter cloacae. The resistance rates of Pseudomonas aeruginosa to meropenem and imipenem increased from 13.1% and 17.7% in the 2015–16 period to 24.5% and 21.0% in the 2019–20 period, respectively. Few agents showed activity against Acinetobacter baumannii. The frequency of imipenem-non-susceptible A. baumannii remained stable (remaining ~70%). CONCLUSION: The rapid spread of carbapenem-resistant K. pneumoniae has been serious in recent years. Conversely, the prevalence of ESBL-producing isolates was decreased. Carbapenems are still effective against gram-negative bacilli causing BSIs, except for A. baumannii. More attention should be given to A. baumannii, considering its high resistance against different classes of antimicrobials.
format Online
Article
Text
id pubmed-9064452
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90644522022-05-04 Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020 Yan, Mengyao Zheng, Bo Li, Yun Lv, Yuan Infect Drug Resist Original Research PURPOSE: The antimicrobial resistance profiles of gram-negative bacilli causing bloodstream infections have changed over time, while comprehensive and real-time surveillance data are limited in China. This study aimed to review the antimicrobial susceptibility trends among main gram-negative bacilli isolated from blood specimens in China. METHODS: From 2011 to 2020, a total of 4352 non-duplicate isolates were collected from 21 tertiary hospitals in 18 provinces or cities across China. Antimicrobial susceptibility testing was conducted by the agar dilution method recommended by the Clinical and Laboratory Standards Institute (CLSI), and the results were interpreted using CLSI criteria. RESULTS: During this 10-year surveillance period, meropenem and imipenem were the most effective agents against Escherichia coli (resistance remaining <5%). The proportion of ESBL-producing isolates in carbapenem-susceptible E. coli displayed a decreasing trend (from 72.9% to 51.2%). The resistance rates of Klebsiella pneumoniae to meropenem and imipenem increased from 3.3% and 1.6% in the 2011–12 period to 15.0% and 15.4% in the 2019–20 period, respectively. Carbapenems and amikacin were the most active agents against Enterobacter cloacae. The resistance rates of Pseudomonas aeruginosa to meropenem and imipenem increased from 13.1% and 17.7% in the 2015–16 period to 24.5% and 21.0% in the 2019–20 period, respectively. Few agents showed activity against Acinetobacter baumannii. The frequency of imipenem-non-susceptible A. baumannii remained stable (remaining ~70%). CONCLUSION: The rapid spread of carbapenem-resistant K. pneumoniae has been serious in recent years. Conversely, the prevalence of ESBL-producing isolates was decreased. Carbapenems are still effective against gram-negative bacilli causing BSIs, except for A. baumannii. More attention should be given to A. baumannii, considering its high resistance against different classes of antimicrobials. Dove 2022-04-29 /pmc/articles/PMC9064452/ /pubmed/35517902 http://dx.doi.org/10.2147/IDR.S358788 Text en © 2022 Yan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yan, Mengyao
Zheng, Bo
Li, Yun
Lv, Yuan
Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020
title Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020
title_full Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020
title_fullStr Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020
title_full_unstemmed Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020
title_short Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020
title_sort antimicrobial susceptibility trends among gram-negative bacilli causing bloodstream infections: results from the china antimicrobial resistance surveillance trial (carst) program, 2011–2020
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064452/
https://www.ncbi.nlm.nih.gov/pubmed/35517902
http://dx.doi.org/10.2147/IDR.S358788
work_keys_str_mv AT yanmengyao antimicrobialsusceptibilitytrendsamonggramnegativebacillicausingbloodstreaminfectionsresultsfromthechinaantimicrobialresistancesurveillancetrialcarstprogram20112020
AT zhengbo antimicrobialsusceptibilitytrendsamonggramnegativebacillicausingbloodstreaminfectionsresultsfromthechinaantimicrobialresistancesurveillancetrialcarstprogram20112020
AT liyun antimicrobialsusceptibilitytrendsamonggramnegativebacillicausingbloodstreaminfectionsresultsfromthechinaantimicrobialresistancesurveillancetrialcarstprogram20112020
AT lvyuan antimicrobialsusceptibilitytrendsamonggramnegativebacillicausingbloodstreaminfectionsresultsfromthechinaantimicrobialresistancesurveillancetrialcarstprogram20112020